Neovasc (NVCN) Shares Gap Down to $0.48

Shares of Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) gapped down before the market opened on Thursday . The stock had previously closed at $0.51, but opened at $0.48. Neovasc shares last traded at $0.46, with a volume of 14817 shares.

NVCN has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Neovasc from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Wednesday, November 21st. ValuEngine downgraded Neovasc from a “buy” rating to a “hold” rating in a report on Monday, February 4th.

The firm has a market capitalization of $14.80 million, a P/E ratio of -0.01 and a beta of 1.62.

A hedge fund recently bought a new stake in Neovasc stock. Virtu Financial LLC purchased a new stake in Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 63,055 shares of the medical equipment provider’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 0.27% of Neovasc at the end of the most recent quarter. 10.26% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Neovasc (NVCN) Shares Gap Down to $0.48” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at

About Neovasc (NASDAQ:NVCN)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Read More: What is the quiet period?

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit